| |
|
 Robert S. McDowell, PhD
Vice President, Research
Robert S. McDowell, PhD, joined 3-V Biosciences in 2008.
Dr. McDowell has 22 years of experience in research and development discovering small molecule drugs in cardiovascular disease, inflammation, and oncology and inflammation, with seven compounds advancing into clinical trials. Prior to joining 3-V, Dr. McDowell occupied positions of increasing responsibility at Sunesis Pharmaceuticals.
As Vice President of Chemistry, he oversaw drug discovery, translational research, and manufacturing functions. Under Dr. McDowell’s leadership, the research organization earned collaboration milestones with corporate partners and successfully transitioned four partnered programs and one internal program from early discovery into development. Before joining Sunesis, Dr. McDowell was a Senior Scientist at Genentech where he developed novel strategies for peptidomimetic design that led to multiple compounds advancing into development. Dr. McDowell also led the Structural Chemistry group at Axys Pharmaceuticals and contributed to the Cathepsin K program currently in Phase 3 trials by Merck. Dr. McDowell has authored over 40 peer-reviewed manuscripts and is an inventor on over 20 issued US patents. Dr. McDowell holds a PhD in Chemistry from the University of California at Berkeley. |
|
